Skip to content

Xencor XNCR Investment Proceeds

Investment Proceeds at other companies

Janux Therapeutics logo
Janux TherapeuticsJANX
$121.31M+288%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$35M-74.5%
Absci Corporation logo
Absci CorporationABSI
$26M+4.0%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$25.51M
Summit Therapeutics logo
Summit TherapeuticsSMMT
$177.29M+10.4%
Arrowhead Research logo
Arrowhead ResearchARWR
$115.34M-2.4%

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+76.3%
Enterprise value$1.23B+55.9%
P/S11×+6.2×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's investment proceeds?
Xencor (XNCR) reported investment proceeds of $99.97M in Q1 2026.
How has Xencor's investment proceeds changed year-over-year?
Xencor's investment proceeds decreased by 16.0% year-over-year, from $118.99M to $99.97M.
What is the long-term trend for Xencor's investment proceeds?
Over 4 years (2021 to 2025), Xencor's investment proceeds has grown at a -4.4% compound annual growth rate (CAGR), from $485.15M to $405.09M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.